Results 151 to 160 of about 79,270 (300)

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

British Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier, David Spähn, David Arturo Juarez Lopez, Judith L. Nono, Judith Seigner, Lisa Jacob, Siegfried Ussar, Robert Lukowski, Andreas L. Birkenfeld, Gencer Sancar   +9 more
wiley   +1 more source

Modulating phosphodiesterase-5 activity to suppress the immunosuppressive mechanisms of myeloid-derived suppressor cells in breast cancer

Breast Cancer Research
Phosphodiesterase-5 (PDE5) inhibitors have been shown to have potential as an adjuvant therapy for cancer. Tadalafil is a potent and selective PDE5 inhibitor that has been shown to inhibit the aggregation of myeloid-derived suppressor cells (MDSC) within
Yingxue Guo, Mengyun Chen, Qi Yuan, Jie Huang, Wen Mao, Xianli Liu, Lu Jin, Lijia Chen, Jingyi Lou, Xia Liu, Qi Pan, Huiying Fu, Qiyang Shou   +12 more
doaj   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Comparison of phosphodiesterase type 5 (PDE5) inhibitors.

International journal of clinical practice, 2007
Of the current options available to treat erectile dysfunction, oral phosphodiesterase type 5 (PDE5) inhibitors are the recommended first-line treatment. This review compares the three currently licensed PDE5 inhibitors: sildenafil citrate (sildenafil), vardenafil HCl (vardenafil) and tadalafil.
openaire   +1 more source

Cytokine Milieu Relevant to Atopic Dermatitis Enhances Epidermal Trypsin‐Like Serine Protease Activity, Which Is Pharmacologically Suppressed in Human Keratinocytes

The Journal of Dermatology, EarlyView.
Shiori Onishi, Yohei Yasutomi, Onon Tsedendorj, Shin Morizane   +3 more
wiley   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

Sildenafil in the treatment of pulmonary hypertension

Vascular Health and Risk Management, 2006
Christopher F Barnett1,2, Roberto F Machado1,21Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA; 2Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health ...
Christopher F Barnett, Roberto F Machado
doaj  

Study Design and Rationale for The Breathe Easier With Tadalafil Therapy for Exercise‐Related Dyspnea in COPD‐PH (BETTER COPD‐PH)

Pulmonary Circulation
Dyspnea, a debilitating symptom of COPD, worsens health‐related quality of life (HRQL), reduces daily physical activity, increases health care utilization, and is more closely associated with survival than airflow limitation. Thus, having treatments that
Elena DeSanti, Matthew Jankowich, Gaurav Choudhary, Alan Morrison, Zachary K. Stanley, Eric Garshick, Marilyn L. Moy, Mohleen Kang, Cherry Wongtrakool, Ruxana T. Sadikot, Edward C. Dempsey, Matthew Griffith, Duc M. Ha, Christopher H. Schmid, Ronald H. Goldstein, Sharon Rounds, the BETTER COPD‐PH Study Group   +16 more
doaj   +1 more source

The recent phosphodiesterase type 5 inhibitors

Human Andrology, 2012
Stefan Ückert, Armin J. Becker, Christian G. Stief, Markus A. Kuczyk, Matthias Trottmann   +4 more
openaire   +1 more source